Epitalon Autoimmune Disease Considerations: What the Clinical Evidence Shows

What the human studies measured

FDA's review located three human studies of epitalon: two sublingual studies in night-shift workers and one injection beside the eye in retinitis pigmentosa [1]. None of these studied people with an autoimmune diagnosis [1].

In the placebo-controlled sublingual study, 75 healthy women aged 40 to 50 were enrolled, mostly night-shift workers; 40 with low melatonin output were split into two groups of 20 and given a spray delivering about 0.5 mg per day or placebo for 20 days [1]. Urinary 6-sulfatoxymelatonin rose about 1.7-fold with epitalon and did not change with placebo, and 83% versus 25% were described as improved in mood and physical condition; sleep was not measured, blinding was not specified, and the study was small and short [1].

In the retinitis pigmentosa study, epitalon was injected beside the eye. The published abstract reports a positive clinical effect in 90% of cases but gives no sample sizes or design details, and the finding has not been replicated [5][6].

Do laboratory findings say anything about autoimmune disease?

In cultured human fetal fibroblasts that lack telomerase, epitalon induced telomerase activity and telomere elongation [7]. Small studies report a rise in melatonin output in older or pineal-impaired subjects, though FDA found that how epitalon changes melatonin in the body is unknown [1]. Neither finding shows whether epitalon helps or harms people with autoimmune disease. A 2026 narrative review searching through September 22, 2026 called epitalon biologically active but clinically unproven, with no adequately powered randomized trial establishing therapeutic efficacy [6].

Safety and regulatory status

FDA's search of its adverse-event database through December 8, 2025 and its food and supplement complaint system through December 5, 2025 retrieved no epitalon reports; FDA concluded there are no clinical data supporting its safety [1]. For subcutaneous injection FDA raised an immunogenicity concern [1]. FDA also warned that, because epitalon activates telomerase and lengthens telomeres, and longer telomeres are generally linked to higher cancer risk, it has a mechanistic potential to be carcinogenic [1].

Epitalon is not FDA-approved and is not a component of an approved drug; its orphan designation for retinitis pigmentosa, granted in 2010, was withdrawn in 2016 [1]. It appears in none of the three categories on FDA's bulk-substance list for state-licensed pharmacies or on the outsourcing-facility list [2][3]. FDA's Pharmacy Compounding Advisory Committee voted on July 24, 2026 in favor of adding it to the bulks list, against FDA staff's recommendation; the vote is non-binding advice, and epitalon is not on the list [8][4]. The HHS enforcement-discretion policy that names epitalon is a draft that does not establish rights and is not binding [4].